Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Coumadin (discontinued in US but name in common use), Jantoven (1)

Analgesic (2) · Classic Psychedelic (1) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Research material (1) · [[:Category:Anticoagulants|Anticoagulant]] (1) · [[:Category:Vitamin_K_antagonists|Vitamin K antagonist]] (1)

None (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Potent 5-HT2A agonist (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000700-QINU`"', '"`UNIQ--vote-00000701-QINU`"', '"`UNIQ--vote-00000702-QINU`"', '"`UNIQ--vote-00000703-QINU`"', '"`UNIQ--vote-00000704-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice (1)

None (2) · 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets (color-coded by strength) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · No fixed maximum; titrated to INR target (1)

None (2) · IV (rarely used; same dose) (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · 30–60 min (PO) (1) · Anticoagulant effect at 24-72 hours; full INR effect 5-7 days (1)

None (2) · 2-5 days after stopping (factor II resynthesis-limited) (1) · 4–6 hours (1)

None (2) · 2.5–3 hours (1) · 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)'"`UNIQ--ref-00000705-QINU`"' (1)

None (2) · ~100% (oral)'"`UNIQ--ref-00000706-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (3) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)